SCHEMBL6239211

SCHEMBL6239211

COc1ccc(C(=O)Nc2ccc3c(c2)c(O)c(C2=NS(=O)(=O)c4ccccc4N2)c(=O)n3CCC(C)C)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.54
HSD17B10 Q99714 1/20 0.54
CYP2C9 P11712 4/20 0.52
NR1I2 O75469 1/20 0.52
CNR2 P34972 2/20 0.40
SMN1; SMN2 Q16637 5/20 0.39
KDM4E B2RXH2 4/20 0.39
LMNA P02545 4/20 0.39
RAB9A P51151 4/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPT P10636 3/20 0.39
HPGD P15428 3/20 0.39
HCRTR1 O43613 2/20 0.39
PAX8 Q06710 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CA12 O43570 2/20 0.38
CA2 P00918 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6242212 0.93 MAPK1 (0.53) MAPK1HSD17B10CYP2C9NR1I2CNR2
SCHEMBL6231895 0.93 MAPK1 (0.58) MAPK1HSD17B10CYP2C9NR1I2CNR2
SCHEMBL6267540 0.91 CYP2C9 (0.61) MAPK1HSD17B10CYP2C9NR1I2CNR2
SCHEMBL6234425 0.89 MAPK1 (0.53) MAPK1HSD17B10CYP2C9NR1I2LMNA
SCHEMBL6234807 0.87 MAPK1 (0.61) MAPK1HSD17B10CYP2C9NR1I2SMN1; SMN2
SCHEMBL6241366 0.87 MAPK1 (0.54) MAPK1HSD17B10CYP2C9NR1I2CNR2
SCHEMBL6230351 0.86 MAPK1 (0.59) MAPK1HSD17B10CYP2C9NR1I2SMN1; SMN2
SCHEMBL6239964 0.85 MAPK1 (0.58) MAPK1HSD17B10CYP2C9NR1I2SMN1; SMN2
SCHEMBL6238240 0.84 MAPK1 (0.61) MAPK1HSD17B10CYP2C9NR1I2SMN1; SMN2
SCHEMBL6236659 0.84 MAPK1 (0.57) MAPK1HSD17B10CYP2C9NR1I2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US claimed
EP-1401443-A4 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP disclosed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US disclosed
EP-1401443-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-03-31 EP disclosed
WO-2002098424-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147739-A1 Novel anti-infectives RPL5, RPL7, RPL35 MAPK1 3699/4885HSD17B10 1428/4885CYP2C9 1218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.